An adaptive trial should be like a driverless car – boring and predictable

On the BBC world service in 2013 there was an account by two technology journalists of going for a ride in the Google “Driverless Car”. They recounted their emotional journey as the Google engineer in the middle of a Californian freeway, in the[…]

How should we test potential treatments for Ebola?

A pressing problem and a very modern dilemma, how should we test potential treatments for Ebola? We know that a double-blind randomised clinical trial (RCT) is the gold standard for generating evidence for, or against, a new drug. In an RCT patients[…]

Report on the current state of play in the adoption of adaptive trials designs by Kenneth Getz of Tufts CSDD

There’s a really good article in Applied Clinical Trials on the state of play in the industry of the use of adaptive clinical trials by Ken Getz of Tufts, click here for full article  reports that in their survey of the industry, about 20% of phase[…]

Patient sub-population effects: The regulator’s dilemma

At the DIA/FDA statistics workshop last week, amongst the many and varied interesting presentations, the one that most caught my eye was Dr Armin Koch’s talk on examples of patient sub-populations. (Dr Koch, of the Hannover Medical School, is a[…]

A maturity model for clinical trial design

Harnessing the Power of Modeling and Simulation

Leadership, decisions and analytics in a VUCA world

Volatility, Uncertainty, Complexity and Ambiguity (VUCA) started life as an acronym in the post-Cold-War world of the US Army. It is now an accurate label capturing the current global business environment. In the commercial world it is becoming[…]


Subscribe to our newsletter

Join over 5,000 thought leaders and experts in R&D, science, engineering and business, giving you access to opinions, case studies and the very latest thought leadership.